| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/16/2002 | US6420473 Acrylic enteric coating compositions |
| 07/16/2002 | US6420468 Pre-polymerization, monomer(s) dissolved in water-miscible aprotic organic solvent forming non-solvent mixture of polymer; prophylactic or curative antibiotics or antiseptic agents |
| 07/16/2002 | US6420436 Imaging contrast media and methods of use |
| 07/16/2002 | US6420431 Methods for treating disordered tissue through agitated delivery of anti-infective compositions |
| 07/16/2002 | US6420394 Topically applied pharmaceutical formulation |
| 07/16/2002 | US6420384 Proton pump inhibitors |
| 07/16/2002 | US6420377 Covalent conjugates of topoisomerase I and topoisomerase II inhibitors |
| 07/16/2002 | US6420355 Hydrophilic organic solvent; mixed mono-, di-, and triglyceride or a transesterified and polyethoxylated vegetable oil; a polyoxyethylene-sorbitan-fatty ester surfactant; emulsion preconcentrate for oral administration |
| 07/16/2002 | US6420354 Sodium channel drugs and uses |
| 07/16/2002 | US6420340 Homogeneous preparation of protein, e.g. leptin, modified at the n-terminal only by an anhydride, e.g. succinic anhydride, ethylenediaminetetraacetic dianhydride; improved solubility; no inflammation at injection sites |
| 07/16/2002 | US6420339 Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| 07/16/2002 | US6420336 Purified antiviral protein, peptide or conjugate encoded by amino acid sequence 90% homologous to seq id no: 2; prophy-lactic or therapeutic inhibition of growth of a virus, such as a retrovirus; human immunodeficiency virus, hiv-1 or hiv-2 |
| 07/16/2002 | US6420176 Composition for delivering DNA into antigen presenting cells |
| 07/16/2002 | US6420157 Expression vector coding enzymatic polypeptide for use in the treatment of inflammation and sexual disorders; for use in laundry detergents |
| 07/16/2002 | US6420126 Tumor specific internalizing antigens and methods for targeting therapeutic agents |
| 07/16/2002 | US6419963 Composition and method for the treatment of diaper rash using natural products |
| 07/16/2002 | US6419957 Crosslinked with monochloroacetic acid or chloroethylamine hydrochloride |
| 07/16/2002 | US6419956 Odor-masking coating for a pharmaceutical preparation |
| 07/16/2002 | US6419955 Process for making bisphosphonate compositions |
| 07/16/2002 | US6419954 Mixture containing gelled polymer |
| 07/16/2002 | US6419952 Composite wall containing liquid active material |
| 07/16/2002 | US6419946 Mixture of oil and ester surfactant; moistuizing skin |
| 07/16/2002 | US6419940 Analgesics; mixture of triethanolamine, aluminum silicates and methyl red |
| 07/16/2002 | US6419913 Topical delivery systems for active agents |
| 07/16/2002 | US6419908 UV-photostabilization of dibenzoylmethane sunscreens by compounding with micronized insoluble screening agents |
| 07/16/2002 | US6419901 Anticancer agents |
| 07/16/2002 | US6419900 Formulation and method for treating neoplasms by inhalation |
| 07/16/2002 | US6419899 Administering drugs |
| 07/16/2002 | CA2171738C Parenteral busulfan for treatment of malignant disease |
| 07/16/2002 | CA2165521C Topical composition containing a p substance antagonist |
| 07/16/2002 | CA2148537C Stable freeze-dried formulation comprising a protein; assay kit |
| 07/16/2002 | CA2116956C Pharmaceutical process |
| 07/16/2002 | CA2095926C Anti-human milk fat globule humanised antibodies |
| 07/11/2002 | WO2002053617A1 Linear block polymer |
| 07/11/2002 | WO2002053616A1 New linear block polymer |
| 07/11/2002 | WO2002053584A1 Stabilized pharmaceutical composition in lyophilized form |
| 07/11/2002 | WO2002053583A2 Amphipathic peptides and their use for transferring substances of interest into cells |
| 07/11/2002 | WO2002053572A1 Delivery systems |
| 07/11/2002 | WO2002053526A1 New compounds for use as intermediates in linear block polymer and new linear block polymer |
| 07/11/2002 | WO2002053197A2 Hot melt adhesives for dermal application |
| 07/11/2002 | WO2002053192A1 Stabilised radiopharmaceutical compositions |
| 07/11/2002 | WO2002053190A2 Particles for inhalation having sustained release properties |
| 07/11/2002 | WO2002053189A2 Immunogenic complex |
| 07/11/2002 | WO2002053188A1 Compositions comprising cyclodextrins and no-releasing drugs |
| 07/11/2002 | WO2002053187A2 Methods and transdermal compositions for pain relief |
| 07/11/2002 | WO2002053185A2 Anti-inflammatory use of polycationic compounds |
| 07/11/2002 | WO2002053184A2 Uses for polycationic compounds as vaccine adjuvants |
| 07/11/2002 | WO2002053177A2 Agents and methods for treating pain |
| 07/11/2002 | WO2002053175A2 Use of botulinum toxin for treatment of articular pathologies |
| 07/11/2002 | WO2002053174A2 Controlled release pharmaceutical systems |
| 07/11/2002 | WO2002053173A2 Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases |
| 07/11/2002 | WO2002053154A1 Pharmaceutical emulsion preparation |
| 07/11/2002 | WO2002053136A1 Sustained release preparations |
| 07/11/2002 | WO2002053130A2 Sustained release drug delivery devices with coated drug cores |
| 07/11/2002 | WO2002053129A1 Sustained release drug delivery devices with prefabricated permeable plugs |
| 07/11/2002 | WO2002053100A2 Pharmaceutical dosage form for oral administration of low molecular weight heparin |
| 07/11/2002 | WO2002053097A2 Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| 07/11/2002 | WO2002053091A2 Medicinal combination of a biguanine (metformin) and arginine |
| 07/11/2002 | WO2002053090A2 Medicinal association of a biguanine (metformin) and arginine |
| 07/11/2002 | WO2002053089A2 Stable skin conditioning compositions containing retinoid boosters |
| 07/11/2002 | WO2002052957A1 Creatine/citric acid compound, method for the production of the same and the use thereof |
| 07/11/2002 | WO2002043665A3 Ahf associated dispersion system and method for preparation |
| 07/11/2002 | WO2002039984A3 Medicine based on anti-hyperglycaemic microcapsules with prolonged release |
| 07/11/2002 | WO2002039980A3 Capsule of cellulose derivatives such as hpmc containing benzimidazole derivatives such as omeprazole |
| 07/11/2002 | WO2002026716A3 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections |
| 07/11/2002 | WO2002020724A3 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 07/11/2002 | WO2002019969A3 (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents |
| 07/11/2002 | WO2002011716A3 Liquid formulation of metformin |
| 07/11/2002 | WO2002011666A3 Derivatives of branched-chain lipophilic molecules and uses thereof |
| 07/11/2002 | WO2002003987A3 Pharmaceutical compositions of estrogenic agents |
| 07/11/2002 | WO2001087262A3 Stabilized steroidal suspension |
| 07/11/2002 | WO2001083781A3 14094, a novel human trypsin family member and uses thereof |
| 07/11/2002 | WO2001078756A3 Agent for postoperative use after the removal of bone tumours |
| 07/11/2002 | WO2001076556A3 Lipid-based drug delivery systems against parasitic infections |
| 07/11/2002 | WO2001068145A3 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| 07/11/2002 | WO2001068141A8 Dispersions of polypeptide conjugates |
| 07/11/2002 | WO2001045577A3 Intervertebral disc treatment devices and methods |
| 07/11/2002 | WO2001034205A3 Use of lytic toxins and toxin conjugates |
| 07/11/2002 | WO2001030397A3 Ultrasound inducement of artial and ventricular rhythms |
| 07/11/2002 | WO2001030392A3 Delivery of proteins across polar epithelial cell layers |
| 07/11/2002 | WO2001021213A3 Inhibition of secretion from non-neuronal cells |
| 07/11/2002 | WO2001017568A3 Bioconjugation in vivo to pulmonary or blood components |
| 07/11/2002 | WO2001017563A3 Integrin-mediated drug targeting |
| 07/11/2002 | WO2001013927A9 Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof |
| 07/11/2002 | WO2001010454B1 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection |
| 07/11/2002 | WO2001010430A9 Use of estrogen compounds for prevention and treatment of ischemic damage |
| 07/11/2002 | WO2001003685A3 Novel prodrugs for antimicrobial amidines |
| 07/11/2002 | WO2000062067A9 Novel transduction molecules and methods for using same |
| 07/11/2002 | US20020091288 Discrete-length polyethylene glycols |
| 07/11/2002 | US20020091270 Sulfonamides containing oxazole and substituted thiophene rings, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure |
| 07/11/2002 | US20020091251 Preparing preefrentially linked chemical intermediates; obtain hyaluronic acid, incubate with glutaraldehyde, recover reaction product |
| 07/11/2002 | US20020091242 Acid-sensitive compounds, their preparation and uses |
| 07/11/2002 | US20020091230 Made from a bis/gamma-hydroxyhydrocarbyl/ ester of terephthalic acid and a phosphorodichloridate; biocompatible before and upon biodegradation |
| 07/11/2002 | US20020091229 Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| 07/11/2002 | US20020091133 Includes proliferation of neural stem and progenitor cells, differentiation of these cells into neurons, and/or survival of these new neurons; preferred compound is N4-((3-(6-oxo-1,6-dihydropurin-9-yl)-1-oxopropyl)amino)benzoic acid |
| 07/11/2002 | US20020091108 Stable salts of O-acetylsalicylic acid with basic amino acids |
| 07/11/2002 | US20020091101 Immunoisolation of a cell; use of biomedically pure, p-GlcNAc of high molecular weight and consistent properties. |
| 07/11/2002 | US20020091091 Method and compositions for solubilization of pentacyclic triterpenes |
| 07/11/2002 | US20020091085 Src SH3 binding peptides and methods of isolating and using same |
| 07/11/2002 | US20020091077 Osteogenic protein is provided alone or dispersed in a biocompatible non-rigid, amorphous carrier having no defined surfaces |